ACHE and Alzheimer disease: Medications sanctioned by the United States Food and Drug Administration for addressing AD primarily consist of acetylcholinesterase inhibitors and N‐methyl‐D‐aspartate receptor antagonists, which are single‐target therapeutic drugs that only alleviate the symptoms and not the disease (Li et al. 2008).